← Back to all signals
RESEARCH PAPER ANALYSIS

Early Symptoms of Language Disorders in Bilingual Parkinson's Disease Patients: Microstructural and Social-Pragmatic Narrative Elements.

This study reports that bilingual early-stage idiopathic Parkinson's patients exhibit microstructural language deficits (lower MLU-M, more morphological errors and verbal fragmentation), pragmatic changes (fewer enrichment expressions, more exclamations), and altered prosody, with bilingualism…

PMID42017696
JournalJournal of speech, language, and hearing research : JSLHR
Publication Date2026-04-22
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This study reports that bilingual early-stage idiopathic Parkinson's patients exhibit microstructural language deficits (lower MLU-M, more morphological errors and verbal fragmentation), pragmatic changes (fewer enrichment expressions, more exclamations), and altered prosody, with bilingualism…

WHY IT MATTERS

Research significance

Offers a noninvasive discourse-level behavioral biomarker for early/subclinical PD detection and patient stratification that could inform clinical assessments and outcome measures in trials, though it does not provide molecular mechanisms or direct therapeutic targets.

ABSTRACT

Source abstract

PURPOSE: This study examined how bilingualism influences early linguistic and pragmatic alterations in idiopathic Parkinson's disease (IPD), integrating group-based and factorial analyses to identify early communicative markers. METHOD: Sixty-five participants (13 bilingual IPD, 14 monolingual IPD, 14 bilingual healthy, 24 monolingual healthy) produced Turkish narratives based on Frog, Where Are You? Group comparisons (Kruskal-Wallis H and Mann-Whitney U tests) were performed across four groups for microstructural indices (mean length of utterance in morphemes [MLU-M], type-token ratio [TTR], morphological errors, verbal fragmentations) and pragmatic markers (enrichment, exclamation, uncertainty, metaphor, emotional terms). Supplementary 2 × 2 factorial analyses (disease: IPD vs. healthy; bilingualism: bilingual vs. monolingual) were conducted to examine main and interaction effects, with acoustic parameters (fundamental frequency [F0] and intensity ranges) included for prosodic evaluation. RESULTS: Group comparisons revealed that bilingual IPD speakers exhibited the lowest MLU-M (p = .012), highest morphological error (p = .036), and greatest verbal fragmentation (p < .001). Pragmatically, they produced fewer enrichment expressions (p = .041) but more exclamations than monolingual IPD participants (p < .001). Acoustic analysis showed reduced but still broader F0 and intensity ranges in bilingual IPD speakers relative to monolingual IPD speakers (p = .012, p = .047). The 2 × 2 factorial analysis confirmed significant main effects of disease on MLU-M and TTR (p < .05) and Disease × Bilingualism interactions for morphological errors and enrichment (p < .05), demonstrating that bilingualism amplified morphosyntactic instability but mitigated prosodic flattening. CONCLUSIONS: Early-stage IPD involves concurrent microstructural and pragmatic decline, with bilingualism exerting both protective and burdening effects. Crucially, the reduction of enrichment expressions (p < .05) emerged as an early and sensitive indicator of pragmatic deterioration in bilingual Parkinson's disease, linking executive-control demands with sociopragmatic incompleteness. Discourse-level analyses combining group-based and factorial approaches thus provide a refined framework for identifying subclinical linguistic-pragmatic changes beyond conventional motor or lexical measures. SUPPLEMENTAL MATERIAL: https://doi.org/10.23641/asha.31999344.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic